Barclays Initiates TMDX at Overweight as Shorts Hold Firm

The short interest angle is the harder backdrop beneath that Street optimism. Bears hold roughly 22.6% of the free float, or about 7.7 million shares, which ORTEX flags as a high-level positioning. That figure has barely moved over the past month, down less than a tenth of a percent, and only edged lower by around 1% on the week. The shorts have not capitulated. Borrowing costs remain low at 0.48%, up around 9% over the past week but still in territory that imposes no meaningful pain on holders of short positions. Availability is ample at 154% of short interest, meaning lenders have more than one and a half times the currently shorted share count still available to lend. None of this describes a market that is anxious about its short exposure, it describes a short position that is comfortable and patient. The ORTEX short score of 75.7 ranks in the 2nd percentile for bearish positioning across the universe, consistent with that read.

Options traders are the sharpest counter-signal to the shorts. The put/call ratio dropped to 0.46 this week, more than 2.5 standard deviations below its 20-day average of 0.64, the lowest reading of the past year. That is a pronounced shift toward calls relative to where this stock has historically sat. For most of September, the PCR ran between 0.62 and 0.76. The collapse to 0.46 coincides almost exactly with the Barclays initiation, suggesting some of the options flow this week reflects new positioning around that catalyst rather than a broader sentiment shift. Whether the move holds or reverts after the initiation news digests is the key tension heading into earnings.

The fundamental debate cuts along familiar lines. Bulls point to the OCS platform's estimated $8 billion addressable market across heart, lung, and liver, full-year 2025 revenues of $605 million growing 37%, and a series of catalysts in 2027 including DENOVO, CHOPS, and OCS Kidney. The June transplant volume data showing growth above 30% month-to-date added confidence that 2026's clinical delays were temporary. Bears argue the platform is narrow, margin pressure in both Service and Product lines is real, and that UBS's revised annual interest expense of around $28.8 million alongside FY26 adjusted EPS of $1.86 leaves the stock expensive on current earnings power. The PE multiple now runs at 38.6x, down 4.9 points over the past month as the stock has drifted, but not yet at a level that resolves the valuation debate. The 90-day EPS momentum factor ranks in the 11th percentile, a weak read that points to deteriorating forward estimate revisions.

One quieter signal worth noting: director David Weill made an open-market purchase of 1,336 shares at $81.63 on September 11, a small but discretionary buy at a price close to current levels. It was not filed under a 10b5-1 plan. The net insider position over the past 90 days is slightly negative in value terms, driven mostly by a director sale in June, so this note should not be over-read. But the purchase lands almost exactly where the stock trades today, and it was the most recent transaction with a real dollar commitment.

Earnings are scheduled for October 30. The prior quarter's reaction was a 6.2% drop on the day followed by a 9.6% recovery over five sessions. The quarter before that produced a 7.1% gain on the day. The pattern is a stock that tends to swing on the print and then reset. With 22% of the float short, comfortable borrow conditions, call options suddenly in demand, and a fresh $120 Overweight initiation on record, the setup into that October 30 print is less about whether the OCS story is intact and more about whether the revenue trajectory for Q3 shows enough momentum to justify the gap between where short sellers and the most optimistic analysts think this stock belongs.